These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Dopamine receptors and antipsychotic drug response. Sunahara RK; Seeman P; Van Tol HH; Niznik HB Br J Psychiatry Suppl; 1993 Dec; (22):31-8. PubMed ID: 7906523 [TBL] [Abstract][Full Text] [Related]
8. [Role of dopamine receptors in the mechanism of action of neuroleptics]. Lavretskaia EF; Kats MM; Baldenkov GN Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):431-5. PubMed ID: 2859724 [TBL] [Abstract][Full Text] [Related]
9. Diversity of dopamine receptors: new molecular and pharmacological developments. Hartman DS; Lanau F Pol J Pharmacol; 1997 Aug; 49(4):191-9. PubMed ID: 9437762 [TBL] [Abstract][Full Text] [Related]
10. [Functional role and pharmacological regulation of the dopaminergic system of the brain]. Raevskiĭ KS Vestn Ross Akad Med Nauk; 1998; (8):19-24. PubMed ID: 9771125 [TBL] [Abstract][Full Text] [Related]
11. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398 [TBL] [Abstract][Full Text] [Related]
12. [Dopaminergic receptors: structural features and functional implications]. Nieoullon A; Amalric M Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S59-68. PubMed ID: 12690665 [TBL] [Abstract][Full Text] [Related]
13. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. Singh AN; Barlas C; Singh S; Franks P; Mishra RK J Psychiatry Neurosci; 1996 Jan; 21(1):29-35. PubMed ID: 8580115 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. Lidow MS; Elsworth JD; Goldman-Rakic PS J Pharmacol Exp Ther; 1997 Apr; 281(1):597-603. PubMed ID: 9103549 [TBL] [Abstract][Full Text] [Related]
15. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
16. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
17. [Clinical psychopharmacology: the example of clozapine (Leponex)]. Péré JJ Encephale; 1995 Jun; 21 Spec No 3():9-12. PubMed ID: 7628347 [TBL] [Abstract][Full Text] [Related]
18. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. Tang L; Todd RD; Heller A; O'Malley KL J Pharmacol Exp Ther; 1994 Jan; 268(1):495-502. PubMed ID: 8301592 [TBL] [Abstract][Full Text] [Related]